You are here: Industry Insights > EMA

News List

EMA’s CHMP Recommends Approval of Merck’s KEYTRUDA® for the Treatment of Patients with Relapsed or R americanpharmaceuticalreview
March 27, 2017
Merck has announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of KEYTRUDA® (pembrolizumab).
Almirall and Sun Pharma announce regulatory filing of tildrakizumab in Europe financialexpress
March 27, 2017
Pivotal Phase 3 data demonstrated potential of Tildrakizumab to offer patients treatment for moderate-to-severe plaque psoriasis without burden of frequent injections
Mereo BioPharma’s BPS-804 drug accepted for participation in EMA’s adaptive pathways programme pharmaceutical-technology
February 22, 2017
UK-based biopharmaceutical company Mereo BioPharma has announced that its BPS-804 drug has been accepted to participate in the European Medicines Agency’s (EMA) adaptive pathways programme.
Ultragenyx and Kyowa Kirin International announce Marketing Authorisation Application for KRN23 pharmaasia
January 23, 2017
Since August 2013, Ultragenyx and Kyowa Hakko Kirin entered into a collaboration and license agreement to develop and commercialise KRN23.
EC ratifies positive opinion for PTC’s Translarna marketing authorisation renewal pharmaceutical-technology
January 13, 2017
The European Commission (EC) has ratified positive opinion for the annual renewal of PTC Therapeutics’ Translarna (ataluren) marketing authorisation for the treatment of nonsense mutation duchenne muscular dystrophy (nmDMD).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 31 32 Next page